Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0021051 (
immunodeficiency
)
71,517
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human
APOBEC3G
(hA3G) is a cytidine deaminase that restricts human
immunodeficiency
virus (HIV)-1 infection in a vif (the virion infectivity factor from HIV)-dependent manner. hA3G from HIV-permissive activated CD4+ T-cells exists as an inactive, high molecular mass (HMM) complex that can be transformed in vitro into an active, low molecular mass (LMM) variant comparable with that of HIV-non-permissive CD4+ T-cells. Here we present low resolution structures of hA3G in HMM and LMM forms determined by small angle x-ray scattering and advanced shape reconstruction methods. The results show that LMM particles have an extended shape, dissimilar to known cytidine deaminases, featuring novel tail-to-tail dimerization. Shape analysis of LMM and HMM structures revealed how symmetric association of dimers could lead to minimal HMM variants. These observations imply that the disruption of cellular HMM particles may require regulation of protein-RNA, as well as protein-protein interactions, which has implications for therapeutic development.
...
PMID:Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. 1707 35
Human
APOBEC3G
(
A3G
), a deoxycytidine deaminase, is a broadly acting antiretroviral factor expressed in a variety of cells. Mitogen activation of CD4 T cells enhances
A3G
expression and leads to recruitment of low molecular mass (LMM)
A3G
, which functions as a post-entry human
immunodeficiency
virus (HIV) restriction factor, into enzymatically inactive, high molecular mass (HMM) RNA-protein complexes that include Staufen RNA-transporting granules. We now report that interleukin-2 (IL-2), IL-15 and, to a lesser extent, IL-7 enhance the expression of
A3G
in peripheral blood lymphocytes and that this effect is blocked by inhibitors of the JAK and MAPK signaling pathways. In mixed cultures of CD4+ T cells containing either HMM or LMM
A3G
, HIV preferentially infected cells containing HMM
A3G
.
A3G
shifted into a HMM complex when IL-2, -7, or -15 was added to resting T cells, likely explaining how cytokine treatment renders resting CD4+ T cells permissive to HIV infection. Similarly, poly(I:C)/tumor necrosis factor-alpha-induced maturation of dendritic cells was associated with a sharp increase in
A3G
expression; however, this induction led to the accumulation of LMM
A3G
. Together, these results highlight the distinct inductive effects of select cytokines on
A3G
gene expression and
A3G
complex assembly that occur in natural cellular targets of HIV infection.
...
PMID:Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. 1711 Mar 77
A host cytidine deaminase,
APOBEC3G
(
A3G
), inhibits replication of human
immunodeficiency
virus type 1 (HIV-1) by incorporating into virions in the absence of the virally encoded Vif protein (Deltavif virions), at least in part by causing G-to-A hypermutation. To gain insight into the antiretroviral function of
A3G
, we determined the quantities of
A3G
molecules that are incorporated in Deltavif virions. We combined three experimental approaches-reversed-phase high-pressure liquid chromatography (HPLC), scintillation proximity assay (SPA), and quantitative immunoblotting-to determine the molar ratio of
A3G
to HIV-1 capsid protein in Deltavif virions. Our studies revealed that the amount of the
A3G
incorporated into Deltavif virions was proportional to the level of its expression in the viral producing cells, and the ratio of the
A3G
to Gag in the Deltavif virions produced from activated human peripheral blood mononuclear cells (PBMC) was approximately 1:439. Based on previous estimates of the stoichiometry of HIV-1 Gag in virions (1400-5000), we conclude that approximately 7 (+/-4) molecules of
A3G
are incorporated into Deltavif virions produced from human PBMCs. These results indicate that virion incorporation of only a few molecules of
A3G
is sufficient to inhibit HIV-1 replication.
...
PMID:Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. 1712 71
The human
immunodeficiency
virus type-1 (HIV-1) accessory protein Vif serves to neutralize the human antiviral proteins apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G (
APOBEC3G
[A3G]) and A3F. As such, the therapeutic blockade of Vif function represents a logical objective for rational drug design. To facilitate such endeavors, we have employed molecular genetics to define features of A3G that are required for its interaction with Vif. Using alanine-scanning mutations and multiple different substitutions at key residues, we confirm the central role played by the aspartic acid at position 128 and identify proline 129 and aspartic acid 130 as important contributory residues. The overall negative charge of this 3-amino-acid motif appears critical for recognition by Vif, as single lysine substitutions are particularly deleterious and a double alanine substitution at positions 128 and 130 is far more inhibitory than single-residue mutations at either position. Our analyses also reveal that the immediately adjacent 4 amino acids, residues 124 to 127, are important for the packaging of A3G into HIV-1 particles. Most important are tyrosine 124 and tryptophan 127, and mutations at these positions can ablate virion incorporation, as well as the capacity to inhibit virus infection. Thus, while pharmacologic agents that target the acidic motif at residues 128 to 130 have the potential to rescue A3G expression by occluding recognition by Vif, care will have to be taken not to perturb the contributions of the neighboring 124-to-127 region to packaging if such agents are to have therapeutic benefit by promoting A3G incorporation into progeny virions.
...
PMID:Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. 1726 97
Cellular cytidine deaminases APOBEC3 family is a group of potent inhibitors for many exogenous and endogenous retroviruses. It has been demonstrated that they induce G to A hypermutations in the nascent retroviral DNA, resulting from the cytosine (C) to uracil (U) conversions in minus-stranded viral DNA. In this report, we have demonstrated that the result of C to U conversion in minus-stranded DNA of human
immunodeficiency
virus type 1 (HIV-1) could trigger a degradation of nascent viral DNA mediated by uracil DNA glycosylases-2 (UNG2) and apurinic/apyrimidinic endonuclease (APE). Since antiviral activity of
APOBEC3G
is partially affected by UNG2 inhibitor Ugi or UNG2-specific short-interfering RNA in virus-producing cells but not target cells, the virion-associated UNG2 most likely mediates this process. Interestingly, as APE-specific short-interfering RNA can also partially inhibit the anti-HIV-1 activity of
APOBEC3G
in virus-producing cells but not in target cells and APE molecules can be detected within HIV-1 virions, it seems that the required APE is also virion-associated. Furthermore, the in vitro cleavage experiment using uracil-containing single-stranded DNA as a template has demonstrated that the uracil-excising catalytic activity of virion-associated UNG2 can remove dU from the uracil-containing viral DNA and leave an abasic site, which could be further cleaved by virion-associated APE. Based upon our observations, we propose that the degradation of
APOBEC3G
-edited viral DNA mediated by virion-associated UNG2 and APE during or after reverse transcription could be partially responsible for the potent anti-HIV-1 effect by
APOBEC3G
in the absence of vif.
...
PMID:Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. 1727 83
APOBEC3G
is an endogenous host restriction factor that inhibits human
immunodeficiency
virus (HIV) replication. The antiviral activity of
APOBEC3G
is dependent upon its incorporation into the virus particle. The mechanisms governing incorporation of
APOBEC3G
into virus particles are not completely understood. In particular, some investigators have reported that
APOBEC3G
interacts directly with the nucleocapsid (NC) subunit of Gag, while others have found that an RNA intermediate is required for Gag-
APOBEC3G
interactions. In this study, we confirmed the RNA dependence of
APOBEC3G
packaging and performed detailed mapping of the determinants within NC that are required for virion incorporation. Surprisingly,
APOBEC3G
packaging did not correlate well with the presence of the N-terminal "I," or interaction, domain within NC. Specifically, Gag constructs containing only the N-terminal region of NC packaged minimal amounts of
APOBEC3G
, while significant levels of
APOBEC3G
packaging were achieved with Gag constructs containing the basic linker region of NC. Furthermore, membrane-binding experiments revealed that the basic linker region was essential for the membrane association of
APOBEC3G
in a Gag-
APOBEC3G
complex. Fluorescence resonance energy transfer was detected between labeled
APOBEC3G
in cells and in particles, indicating that
APOBEC3G
is packaged as a multimer that is bound to packaged RNA. Regions of
APOBEC3G
-Gag colocalization at the plasma membrane were detected that were distinct from the punctate cytoplasmic bodies where
APOBEC3G
accumulates within the cell. Together, our results indicate that
APOBEC3G
multimerizes in an RNA-dependent fashion and that RNA-
APOBEC3G
multimers are recruited to the plasma membrane and subsequently into virion particles by Gag.
...
PMID:APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. 1734 95
Human cytidine deaminase APOBEC3F (A3F) has broad anti-viral activity against hepatitis B virus and retroviruses including human
immunodeficiency
virus type 1. However, its regulation in viral natural target cells such CD4+ T lymphocytes, macrophages, and primary liver cells has not been well studied. Here we showed that A3F was up-regulated by interferon (IFN)-alpha in primary hepatocytes and multiple liver cell lines as well as macrophages. Although the IFN-alpha signaling pathway was active in T lymphoid cells and induction of other IFN stimulated genes such as PKR was detected, A3F and
APOBEC3G
(
A3G
) were not induced by IFN-alpha in these cells. Thus, additional factors other than known IFN-stimulated genes also regulated IFN-alpha-induced A3F expression distinctly. A3F and
A3G
expression levels in primary hepatocytes, especially after IFN-alpha stimulation, were comparable to those in CD4+ T lymphocytes in some individuals. Significant variations of A3F and
A3G
expression in primary hepatocytes from various subjects were observed. Individual variations in A3F and/or
A3G
regulation and expression might influence the clinical outcomes of hepatitis B infection.
...
PMID:Cell-specific regulation of APOBEC3F by interferons. 1741 86
APOBEC3G
(
A3G
) is a single-stranded DNA cytidine deaminase that targets retroviral minus-strand DNA and has potent antiviral activity against diverse retroviruses. However, the mechanisms of
A3G
antiviral functions are incompletely understood. Here we demonstrate that
A3G
, A3F, and, to a lesser extent, the noncatalytic A3GC291S block human
immunodeficiency
virus type 1 (HIV-1) replication by interfering with proviral DNA formation. In HIV-1 virions,
A3G
interacted with HIV-1 integrase and nucleocapsid, key viral factors for reverse transcription and integration. Unlike
A3G
, the weak antiviral A3C cytidine deaminase did not interact with either of these factors and did not affect viral reverse transcription or proviral DNA formation. Thus, multiple steps of the HIV-1 replication cycle, most noticeably the formation of proviral DNA, are inhibited by both cytidine deamination-dependent and -independent mechanisms.
...
PMID:Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. 1742 47
Encapsidation of host restriction factor
APOBEC3G
(
A3G
) into vif-deficient human
immunodeficiency
virus type 1 (HIV-1) blocks virus replication at least partly by C-to-U deamination of viral minus-strand DNA, resulting in G-to-A hypermutation.
A3G
may also inhibit HIV-1 replication by reducing viral DNA synthesis and inducing viral DNA degradation. To gain further insight into the mechanisms of viral inhibition, we examined the metabolism of
A3G
-exposed viral DNA. We observed that an overall 35-fold decrease in viral infectivity was accompanied by a five- to sevenfold reduction in viral DNA synthesis. Wild-type
A3G
induced an additional fivefold decrease in the amount of viral DNA that was integrated into the host cell genome and similarly reduced the efficiency with which HIV-1 preintegration complexes (PICs) integrated into a target DNA in vitro. The
A3G
C-terminal catalytic domain was required for both of these antiviral activities. Southern blotting analysis of PICs showed that
A3G
reduced the efficiency and specificity of primer tRNA processing and removal, resulting in viral DNA ends that are inefficient substrates for integration and plus-strand DNA transfer. However, the decrease in plus-strand DNA transfer did not account for all of the observed decrease in viral DNA synthesis associated with
A3G
. These novel observations suggest that HIV-1 cDNA produced in the presence of
A3G
exhibits defects in primer tRNA processing, plus-strand DNA transfer, and integration.
...
PMID:Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. 1742 71
The mammalian APOBEC3 proteins are cytidine deaminases that function as inhibitors of retrovirus replication and retrotransposon mobility. An issue that has remained controversial is whether the editing of deoxycytidine residues to deoxyuridine is necessary and sufficient for this inhibition or whether APOBEC3 proteins also exert a second, distinct inhibitory mechanism. Here, we present an analysis of the ability of mutants of
APOBEC3G
and APOBEC3B, both of which contain two consensus cytidine deaminase active sites, to inhibit the replication of human
immunodeficiency
virus. Our data confirm that
APOBEC3G
only contains a single, carboxy-terminal active site but, surprisingly, reveal that both cytidine deaminase consensus sequences in APOBEC3B are enzymatically active. Enzymatically inactive mutant forms of
APOBEC3G
and APOBEC3B were found to retain the ability to inhibit the infectivity of HIV-1 virions produced in their presence by approximately 4-fold and approximately 8-fold, respectively. While this inhibition was significantly less than the level seen with wild-type forms of A3G or A3B, these data, nevertheless argue that the inhibition of HIV-1 by APOBEC3 proteins is at least partly independent of DNA editing.
...
PMID:The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. 1743 55
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>